Related Experiment Video
Updated: Jun 12, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Protein kinase gene expression profiling and in vitro functional experiments identify novel potential therapeutic
Monica Messina1, Sabina Chiaretti, Simona Tavolaro
1Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
Background:
Despite recent improvements in the treatment of acute lymphoblastic leukemia (ALL), adult patients still have an overall poor outcome. The future of ALL management relies on the introduction of novel targeted therapies. The authors sought to assess if protein kinases (PKs), frequently deregulated in cancer, show an altered expression pattern and can be considered as suitable therapeutic targets in adult ALL.
Methods:
The authors studied the PK gene expression profile by oligonucleotide arrays in 133 adult ALL samples at the onset of the disease and subsequently performed in vitro experiments to evaluate the sensitivity to first- and second-generation PK inhibitors of a set of ALL cell lines, as well as of primary ALL cells.
Results:
The study documents a distinctive PK signature for different adult ALL subgroups; the PKs identified include several tyrosine kinase (TK) genes, especially in E2A/PBX+ B-lineage ALL (B-ALL), B-ALL without known molecular abnormalities, and T-lineage ALL. Consistently, cell lines and primary samples belonging to these groups proved susceptible to TK inhibitors.
Conclusions:
These results indicate that second-generation TK inhibitors may be effective in ALL subsets other than BCR/ABL+B-ALL and provide the rationale for testing the impact of the newly developed TK inhibitors in the management of adult ALL patients.
Insights
Protein kinases (PKs) are potential therapeutic targets in adult acute lymphoblastic leukemia (ALL). This study identified a distinct PK signature in ALL subgroups, showing susceptibility to tyrosine kinase (TK) inhibitors, suggesting new treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Adult acute lymphoblastic leukemia (ALL) treatment outcomes remain poor despite recent advances.
- Novel targeted therapies are crucial for improving adult ALL management.
- Protein kinases (PKs) are frequently deregulated in cancer and represent potential therapeutic targets.
Purpose of the Study:
- To investigate the expression profile of PKs in adult ALL.
- To determine if PKs are suitable therapeutic targets in adult ALL.
- To assess the efficacy of PK inhibitors in adult ALL.
Main Methods:
- Oligonucleotide arrays were used to analyze PK gene expression in 133 adult ALL samples.
- In vitro experiments evaluated the sensitivity of ALL cell lines and primary cells to PK inhibitors.
- First- and second-generation PK inhibitors were tested.
Main Results:
- A distinct PK signature was identified across different adult ALL subgroups.
- Tyrosine kinase (TK) genes were notably altered, particularly in E2A/PBX+ B-lineage ALL, B-ALL without known molecular abnormalities, and T-lineage ALL.
- ALL cell lines and primary samples from these subgroups showed susceptibility to TK inhibitors.
Conclusions:
- Second-generation TK inhibitors demonstrate potential efficacy in specific adult ALL subsets beyond BCR/ABL+ B-ALL.
- These findings provide a rationale for evaluating novel TK inhibitors in adult ALL treatment.
- Targeting specific PKs offers a promising avenue for improving outcomes in adult ALL.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...